Marina Alberto
Marina Alberto, PhD, holds a robust academic background in Biotechnology, earning her Bachelor’s Degree and PhD in Science and Technology from Quilmes National University in Argentina. Her research spans cancer immunotherapy, glycan profiling, and vaccine development, including innovative projects on pediatric leukemia diagnosis and cancer-associated carbohydrate-mimetic vaccines. Marina has also contributed extensively to publications in oncology, immunology, and biosimilar development.
She currently serves as a Technical Support and Sales Specialist at Assay Genie.
Connect with Marina or explore her work:
Recent Blogs by Marina:
What You Need to Know About IndatuximabWhat is Indatuximab?Indatuximab ravtansine is an experimental monoclonal antibody-drug conjugate (ADC) that targets CD138, a protein highly expressed on the surface of certain cancer cells, including multiple myeloma and some solid tumors.What is the mechanism of action [...]
Key Facts About GemtuzumabWhat is Gemtuzumab?Gemtuzumab is an antibody-drug conjugate (ADC) targeting CD33, a protein expressed on the surface of myeloid cells. It is widely recognized for its role in treating acute myeloid leukemia (AML).How does Gemtuzumab work?Gemtuzumab binds to CD33-positive cells and [...]
Key Facts About BrentuximabWhat is Brentuximab?Brentuximab is a monoclonal antibody targeting CD30, commonly used in the treatment of Hodgkin lymphoma and systemic anaplastic large cell lymphoma.What is the mechanism of action for Brentuximab?Brentuximab vedotin works by delivering a cytotoxic agent to CD30-positive cells, [...]
Publications by Marina: